Two New Dosage Strengths of Suboxone Approved

Reckitt Benckiser announced FDA approval of the 4mg/1mg and 12mg/3mg dosage strengths of Suboxone (buprenorphine and naloxone) sublingual film.

Suboxone sublingual film is indicated for maintenance treatment of opioid dependence in conjunction with counseling and psychosocial support. Buprenorphine, a partial opioid agonist, helps reduce opioid use and increases retention in treatment by managing withdrawal symptoms and reducing cravings. Naloxone, an opioid antagonist, minimizes its attractiveness for deliberate misuse.

Suboxone sublingual film is already available in 2mg/0.5mg and 8mg/2mg dosage strengths. The new 4mg/1mg and 12mg/3mg strengths of Suboxone sublingual film will be available later this year.  

For more information call (800) 444-7599 or visit